肝切除术与化疗栓塞治疗中晚期肝细胞癌的比较:高质量研究的Meta分析
该Meta分析纳入18项高质量研究共5,986例中晚期(BCLC B/C期)肝细胞癌患者,比较初次肝切除(PH)与经动脉化疗栓塞(TACE)的生存结局。结果显示PH较TACE显著改善总生存(HR 0.59,95%CI 0.51-0.67,P<0.00001,I²=84%),BCLC B期和C期亚组均一致。结论提示手术切除可为中晚期患者带来生存获益。
要点
- 中晚期(BCLC B/C期)肝细胞癌患者中,初次肝切除较TACE显著改善总生存(HR 0.59,95%CI 0.51-0.67)。
- BCLC B期和C期亚组中肝切除的总生存获益均显著(HR分别为0.53和0.67)。
- 肝切除组5年生存率在BCLC B/C期、B期和C期均显著高于TACE组(OR分别为2.71、2.77和3.03)。
核心结论
- 该Meta分析提示,手术切除可为中晚期肝细胞癌患者带来生存获益,相关证据可能有助于基于不同可切除性定义选择治疗方式。
研究设计与样本
- 通过数据库检索纳入18项高质量研究,包括1项随机对照试验、5项倾向性评分匹配的非随机对照试验和12项非随机对照试验,共比较5,986例接受初次肝切除或TACE患者后的生存结局。
主要发现
- 在BCLC B/C期患者中,肝切除较TACE显著改善生存(HR 0.59,95%CI 0.51-0.67,P<0.00001,I²=84%)。
- BCLC B期患者中肝切除较TACE总生存显著更优(HR 0.53,95%CI 0.43-0.65,P<0.00001,I²=77%)。
- BCLC C期患者中肝切除较TACE总生存显著更优(HR 0.67,95%CI 0.59-0.77,P<0.00001,I²=79%)。
- 肝切除组5年生存率在BCLC B/C期、B期和C期均显著高于TACE组(OR分别为2.71、2.77和3.03,均P<0.00001)。
- 亚组分析、敏感性分析和Meta回归分析中生存获益持续存在,研究间异质性保持恒定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间异质性较高(BCLC B/C期I²=84%,B期I²=77%,C期I²=79%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate- to advanced-stage (BCLC stage B/C) HCC to determine the current evidence. Through a database search, we included 18 high-quality studies (one randomized controlled trial [RCT], five propensity-score matching nonrandomized comparative trials [NRCTs], and 12 NRCTs) that compared survival outcomes of 5,986 patients after PH and TACE. We found significant survival benefits for PH over TACE in BCLC stage B/C patients (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.51-0.67; P < 0.00001; I2 = 84%). According to the BCLC, both stage B and stage C patients showed significantly better overall survival (OS) for PH compared to TACE (HR, 0.53; 95% CI, 0.43-0.65; P < 0.00001; I2 = 77%; HR, 0.67; 95% CI, 0.59-0.77; P < 0.00001; I2 = 79%, respectively). Five-year survival rates for PH were significantly higher than those for TACE in BCLC stage B/C, stage B, and BCLC stage C patients (odds ratio [OR], 2.71, 2.77, and 3.03, respectively; all P < 0.00001). Survival benefits persisted across subgroup, sensitivity, and metaregression analyses; interstudy heterogeneity remained constant. CONCLUSION: This meta-analysis suggests that surgical resection provides survival benefits in patients with intermediate- to advanced-stage HCC. The evidence found herein may assist in the choice of treatment modality based on diverse definitions of operability. (Hepatology 2018).
引用
- Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018. PMID: 29543988. doi:10.1002/hep.29883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。